Comparative Pharmacology
Head-to-head clinical analysis: INTEGRILIN versus KENGREAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INTEGRILIN versus KENGREAL.
INTEGRILIN vs KENGREAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible antagonist of the platelet glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation by preventing fibrinogen binding.
Cangrelor is a reversible, direct-acting P2Y12 platelet receptor antagonist that inhibits ADP-mediated platelet activation and aggregation.
Acute coronary syndrome: IV bolus of 180 mcg/kg, followed by continuous IV infusion of 2 mcg/kg/min for up to 72 hours. Percutaneous coronary intervention: IV bolus of 180 mcg/kg immediately before PCI, followed by continuous IV infusion of 2 mcg/kg/min for up to 18-24 hours, with a second 180 mcg/kg bolus 10 minutes after the first.
10 mcg/kg intravenous bolus over 1-2 minutes, followed by 0.1 mcg/kg/min continuous intravenous infusion for 2-4 hours.
None Documented
None Documented
Terminal elimination half-life: ~2.5 hours (2-3 hours) after intravenous administration; clinical context: rapid clearance allows return of platelet function within 4 hours after infusion cessation.
Terminal elimination half-life is approximately 3–6 minutes (mean 3.3 minutes), allowing rapid recovery of platelet function within 60 minutes of infusion cessation.
Renal: ~50% as unchanged drug and metabolites, Biliary/fecal: minimal; total clearance approximately 55-58% renal.
Cangrelor is metabolized via rapid dephosphorylation to its major metabolite, a nucleoside, which is further degraded; approximately 58% of the dose is excreted in urine as unchanged cangrelor and metabolites, with <35% in feces.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent